Farmacologia de drogas vasoativas
DOI:
https://doi.org/10.11606/issn.2317-0190.v17i1a103306Palavras-chave:
Doenças Vasculares Periféricas, Farmacologia, Literatura de Revisão como AssuntoResumo
As doenças vasculares periféricas (DVPS) caracterizam-se como um problema de circulação nas veias, artérias e sistema linfático. O tratamento primordial para as DVPS é a mudança de hábitos de vida, alimentação e prática de atividade física. A terapia farmacológica inclui a utilização de drogas vasoativas, as quais são utilizadas nas arteriopatias e nas doenças veno-linfáticas. O objetivo deste estudo foi pesquisar em literatura científica sobre a utilização e farmacologia das drogas vasoativas, enfatizando a eficácia da administração e ação local dessas drogas.
Downloads
Referências
Oales JA, Brown NJ. Treatment of myocardial ischemia. In: Hardmons J. Goodman and Gillman's the pharmacologic basis of therapeutics. 11th ed. Columbus, OH: McGraw Hill; 2006. p. 871.
Rang HP, Dale MM, Ritter JM, Flower RJ. Farmacologia. 6th. Rio de Janeiro: Elsevier; 2007.
Stücker M, Falkenberg M, Reuther T, Altmeyer P, Lübbers DW. Local oxygen content in the skin is increased in chronic venous incompetence. Microvasc Res. 2000;59(1):99-106.
Araújo M. Drogas que visam agir na circulação periférica. In: Silva P. Farmacologia. Rio de Janeiro: Guanabara Koogan; 2002. p.682-8.
Dominguez-Jimenez C, Sancho D, Nieto M, Montoya Maria C, Barreiro O, Sanchez-Madrid F, et al. Effect of pentoxifylline on polarization and migration of human leukocytes. J Leukoc Biol. 2002;71(4):588-96.
Jacoby D, Mohler ER III. Drug Treatment of Intermittent Claudication. Drugs. 2004;64(15):1657-70.
Dorazil-Dudzik M, Mika J, Schafer MK-H, Li Y, Obara I, Wordliczek J, et al. The Effects of Local Pentoxifylline and Propentofylline Treatment on Formalin-Induced Pain and Tumor Necrosis Factor-Messenger RNA Levels in the Inflamed Tissue of the Rat Paw. Anesth Analg. 2004;98(6):1566-73.
Wordliczek J, Szczepanik AM, Banach M, Turchan J, Zembala M, Siedlar M, et al. The effect of pentoxifiline on post - injury hyperalgesia in rats and postoperative pain in patients. Life Sci. 2000;66(12):1155-64.
Wollina U, Abdel-Naser MB, Mani R. A Review of the microcirculation in skin in patients with chronic venous insufficiency: The problem and the evidence available for therapeutic options. Int J Low Extrem Wounds. 2006;5(5):169-80.
Conte MS. Buflomedil in peripheral arterial disease: trials and tribulations. Circulation. 2008;117(6):717-9
De Backer TL, Bogaert M, Vander Stichele R. Buflomedil for intermittent claudication. Cochrane Database Syst Rev. 2008;(1):CD000988.
Conners MS, Money SR. Can claudication be improved with medication? Semin Vasc Surg. 2002;15(4):237-44.
Tiwary AK, Sapra B, Jain S. Innovations in transdermal drug delivery: formulations and techniques. Recent Pat Drug Deliv Formul. 2007;1(1):23-36.
Ahad A, Aqil M, Kohli K, Chaudhary H, Sultana Y, Mujeeb M, et al. Chemical penetration enhancers: a patent review. Expert Opin Ther Pat. 2009;19(7):969-88.
Nounou MI, El-Khordagui LK, Khalafallah NA, Khalil SA. Liposomal formulation for dermal and transdermal drug delivery: past, present and future. Recent Pat Drug Deliv Formul. 2008;2(1):9-18.
Rizwan M, Aqil M, Talegaonkar S, Azeem A, Sultana Y, Ali A. Enhanced transdermal drug delivery techniques: an extensive review of patents. Recent Pat Drug Deliv Formul. 2009;3(2):105-24.
Roesken F, Uhl E, Curri SB, Menger MD, Messmer K. Acceleration of wound healing by topical drug delivery via liposomes. Langenbecks Arch Surg. 2000;385(1):42-9.
Uhl E, Rösken F, Curri SB, Menger MD, Messmer K. Reduction of skin flap necrosis by transdermal application of buflomedil bound to liposomes. Plast Reconstr Surg. 1998;102(5):1598-604.
Wichers IM, Di Nisio M, Büller HR, Middeldorp S. Treatment of superficial vein thrombosis to prevent deep vein thrombosis and pulmonary embolism: a systematic review. Haematologica. 2005;90(5):672-7.
Superficial Thrombophlebitis Treated By Enoxaparin Study Group. A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med. 2003;163(14):1657-63.
Jones H, Paul W, Page CP. The effects of heparin and related molecules on vascular permeability and neutrophil accumulation in rabbit skin. Br J Pharmacol. 2002;135(2):469-79.
Metsavaht L, Metsavaht O, Metsavaht R. Mesoterapia anátomo-clínica na dor músculo-esquelética. In: Teixeira MJ. Dor: contexto interdisciplinar. Curitiba: Maio: 2003. p. 673-88.
Baskys A, Hou AC. Vascular dementia: pharmacological treatment approaches and perspectives. Clin Interv Aging. 2007;2(3):327-35.
Gomaa A, Eissa M, El-Gebaley A. The effect to topically applied vasoactive agents and testosterone versus testosterone in the treatment of erectile dysfunction in aged men with low sexual interest. Int J Impot Res. 2001;13(2):93-9.
Gomaa A, Shalaby M, Osman M, Eissa M, Eizat A, Mahmoud M, et al. Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate, and co-dergocrine mesylate. BMJ. 1996;312(7045):1512-5.
Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol. 2002;168(2):621-6.
Fitch WP3rd, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease - a placebo-controlled pilot study. J Sex Med. 2007;4(2):477-84.
Reich S, Altmeyer P, Stücker M. Systemic therapy of chronic venous diseases. Hautarzt. 2006;57(1):9-10,12-8.
Martinez MJ, Bonfill X, Moreno RM, Vargas E, Capellà D. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2005;(3):CD003229.
Priollet P, Boisseau MR. Drugs for veno-lymphatic insufficiency. Rev Prat. 2000;50(11):1195-8.
Gohel MS, Davies AH. Pharmacological agents in the treatment of venous disease: an update of the available evidence. Curr Vasc Pharmacol. 2009;7(3):303-8.
Badger C, Preston N, Seers K, Mortimer P. Benzopyrones for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. 2004;(2):CD003140.
Xu F, Zeng W, Mao X, Fan GK. The efficacy of melilotus extract in the management of postoperative ecchymosis and edema after simultaneous rhinoplasty and blepharoplasty. Aesthetic Plast Surg. 2008;32(4):599-603.
Godin B, Touitou E. Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models. Adv Drug Deliv Rev. 2007;59(11):1152-61.
Minghetti P, Casiraghi A, Cilurzo F, Montanari L. Development of local patches containing melilot extract and ex vivo-in vivo evaluation of skin permeation. Eur J Pharm Sci. 2000;10(2):111-7.
Consoli A. Chronic venous insufficiency: an open trial of FLEBS Crema. Minerva Cardioangiol. 2003;51(4):411-6.
Pleşca-Manea L, Pârvu AE, Pârvu M, Taămaş M, Buia R, Puia M. Effects of Melilotus officinalis on acute inflammation. Phytother Res. 2002;16(4):316-19.
Zhao L, Tao JY, Zhang SL, Jin F, Pang R, Dong JH. Nbutanol extract from melilotus suaveolens ledeb affects pro- and anti-inflammatory cytokines and mediators. Evid Based Complement Alternat Med. 2007;14:1-10.
Tao JY, Zheng GH, Zhao L, Wu JG, Zhang XY, Zhang SL, et al. Anti-inflammatory effects of ethyl acetate fraction from melilotus suaveolens ledeb on LPSstimulated RAW 264.7 cells. J Ethnopharmacol. 2009;123(1):97-105.
Zhao L, Tao JY, Zhang SL, Pang R, Jin F, Dong JH, et al. Inner anti-inflammatory mechanisms of petroleum ether extract from Melilotus suaveolens Ledeb. Inflammation. 2007;30(6):213-23.
Belcaro G, Cesarone MR, Ledda A, Cacchio M, Ruffini I, Ricci A, et al. 5-Year control and treatment of edema and increased capillary filtration in venous hypertension and diabetic microangiopathy using O-(betahydroxyethyl)-rutosides: a prospective comparative clinical registry. Angiology. 2008;59 Suppl 1:14S-20S.
Incandela L, Belcaro G, Renton S, DeSanctis MT, Cesarone MR, Bavera P, et al. HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial. J Cardiovasc Pharmacol Ther. 2002;7 Suppl 1:S7-S10.
Cesarone MR, Incandela L, DeSanctis MT, Belcaro G, Griffin M, Ippolito E, et al. Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized, dose-ranging trial. J Cardiovasc Pharmacol Ther. 2002;7 Suppl 1:S21-4.
Cesarone MR, Belcaro G, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, et al. HR, 0-(beta-hydroxyethyl)-rutosides; (Venoruton): rapid relief of signs/symptoms in chronic venous insufficiency and microangiopathy: a prospective, controlled study. Angiology. 2005;56(2):165-72.
Cesarone MR, Belcaro G, Pellegrini L, Ledda A, Di Renzo A, Vinciguerra G, et al. HR, 0-(beta-hydroxyethyl)-rutosides, in comparison with diosmin+hesperidin in chronic venous insufficiency and venous microangiopathy: an independent, prospective, comparative registry study. Angiology. 2005;56(1):1-8.
Belcaro G, Cesarone MR, Ledda A, Cacchio M, Ruffini I, Ricci A, et al. O-(beta-hydroxyethyl)-rutosides systemic and local treatment in chronic venous disease and microangiopathy: an independent prospective comparative study. Angiology. 2008;59 Suppl 1:7S-13S.
Vanscheidt W, Rabe E, Naser-Hijazi B, Ramelet AA, Partsch H, Diehm C, et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa. 2002;31(3):185-90
Celik A, Ersoy OF, Ozkan N, Kayaoglu HA, Ozugurlu F, Cakir EA, et al. Comparison of the effects of troxerutin and heparinoid on flap necrosis. J Plast Reconstr Aesthet Surg. 2009:[Epub ahead of print].
Laemmel E, Stücker O, Pons C, Duverger JP, Dedieu F, Leutenegger E. Microcirculatory consequences of a venous striction in the rat. Effect of a coumarine-rutine association. J Mal Vasc. 1998;23(3):176-82.
Wetzel D, Menke W, Dieter R, Smasal V, Giannetti B, Bulitta M. Escin/diethylammonium salicylate/heparin combination gels for the topical treatment of acute impact injuries: a randomised, double blind, placebo controlled, multicentre study. Br J Sports Med. 2002;36(3):183-8.
Pabst H, Segesser B, Bulitta M, Wetzel D, Bertram S. Efficacy and tolerability of escin/diethylamine salicylate combination gels in patients with blunt injuries of the extremities. Int J Sports Med. 2001;22(6):430-6.
Cesarone MR, De Sanctis MT, Incandela L, Belcaro G, Griffin M. Microvascular changes in venous hypertension due to varicose veins after standardized application of Essaven gel--a placebo-controlled, randomized study. Angiology. 2001;52 Suppl 3:S11-6.
De Sanctis MT, Incandela L, Belcaro G, Cesarone MR. Topical treatment of venous microangiopathy in patients with venous ulceration with Essaven gel -a placebo-controlled, randomized study. Angiology. 2001;52 Suppl 3:S29-34.
De Sanctis MT, Cesarone MR, Incandela L, Belcaro G, Griffin M. Treatment of superficial vein thrombophlebitis of the arm with Essaven gel - a placebo-controlled, randomized study. Angiology. 2001;52 Suppl 3:S63-7.
Belcaro G, Cesarone MR, Dugall M. Microcirculatory efficacy of topical treatment with aescin + essential phospholipids gel in venous insufficiency and hypertension: new clinical observations. Angiology. 2004;55 Suppl 1:S1-5.
Cesarone MR, Belcaro G, Ippolito E, Ricci A, Ruffini M, Dugall M. Microcirculatory efficacy of topical treatment with aescin + essential phospholipids gel on transcutaneous PO2 in venous insufficiency. Angiology. 2004;55 Suppl 1:S7-10.
Ricci A, Ruffini I, Cesarone MR, Cornelli U, Corsi M, Belcaro G, Ippolito E, Dugall M. Variations in plasma free radicals with topical aescin + essential phospholipids gel in venous hypertension: new clinical data. Angiology. 2004;55 Suppl 1:S11-4.
Ruffini I, Belcaro G, Cesarone MR, Dugall M. Efficacy of topical treatment with aescin + essential phospholipids gel in venous insufficiency and hypertension. Angiology. 2004;55 Suppl 1:S19-21.
Misra MC, Imlitemsu. Drug treatment of haemorrhoids. Drugs. 2005;65(11):1481-91.
Koksal C, Bozkurt AK, Ustundag N, Konukoglu D, Musellim B, Sirin G, et al. Attenuation of acute lung injury following lower limb ischemia/reperfusion: the pharmacological approach. J Cardiovasc Surg (Torino). 2006;47(4):445-9.
Cuevas P, Sanchez I, Lozano RM, Gimenez-Gallego G. Dobesilate is an angiogenesis inhibitor. Eur J Med Res. 2005;10(9):369-72.
Iriz E, Vural C, Ereren E, Poyraz A, Erer D, Oktar L, et al. Effects of calcium dobesilate and diosmin-hesperidin on apoptosis of venous wall in primary varicose veins. Vasa. 2008;37(3):233-40.
Martinez MJ, Bonfill X, Moreno RM, Vargas E, Capellà D. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2005;(3):CD003229.
Flota-Cervera F, Flota-Ruiz C, Treviño C, Berber A. Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology. 2008l;59(3):352-6.
Khadzhaĭ IaI, Chaĭka LA. Mechanism of the microcirculatory effects of ethyl-3,5,6-tri-O-benzyl-D-glucofuranoside. Farmakol Toksikol. 1983;46(2):72-5.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2010 Acta Fisiátrica
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
